Últimas noticias sobre Junee (NASDAQ:JUNE) Bolsa

Cambria ETF Trust ETF

Junee

Junee Ltd is a holding company that operates through its subsidiary. It is engaged in providing design, fit-out, repair, and maintenance services for commercial and residential buildings. The design services include both the consultation with its staff and the actual design work. Fit-out works include installing protective materials to cover floors or walls, installing or constructing partition walls, installing switches, power outlets, telephone wiring, computer outlet covers, and other electrical and wiring works. Repair and maintenance works include, among other things, replacement of fixtures and fittings, repair and maintenance of cupboards and shelves, and repainting walls and ceilings. Geographically, the company derives all of its revenue from its customers in Hong Kong.

Junee Ltd

WIIM

AEVA

Aeva Technologies shares are trading higher after Morgan Stanley raised its price target on the stock from $5.22 to $11.

Stifel analyst Stephen Gengaro maintains Rivian Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) with a Buy and raises the price target from $16 to $18.

News

Price Target

Analyst Ratings

RIVN

Stifel Maintains Buy on Rivian Automotive, Raises Price Target to $18

NexGel (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXGL#NASDAQ">NXGL</a>) will release its quarterly earnings report on Tuesday, 2025-05-13. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate NexGel to report an earnings per share (EPS) of $-0.10.
Investors in NexGel are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Past Earnings Performance</h3>
The company's EPS beat by $0.02 in the last quarter, leading to a 1.94% drop in the share price on the following day.
Here's a look at NexGel's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.13</td>
<td>-0.10</td>
<td>-0.14</td>
<td>-0.18</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.11</td>
<td>-0.11</td>
<td>-0.14</td>
<td>-0.14</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-2.0%</td>
<td>-3.0%</td>
<td>-6.0%</td>
<td>-2.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1747073536_0.png" alt="eps graph" />
<h3>Performance of NexGel Shares</h3>
Shares of NexGel were trading at $2.59 as of May 09. Over the last 52-week period, shares are up 19.47%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/NXGL/earnings">To track all earnings releases for NexGel visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

NXGL

A Peek at NexGel's Future Earnings

Advantage Solutions shares are trading lower after the company reported a Q1 EPS miss.

Life360 will invest $25 million in Aura and the Two Companies Enter a Commercial Agreement on Key Go-to-Markets
BOSTON and SAN FRANCISCO, May 12, 2025 /PRNewswire/ -- <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4425658-1&amp;h=3539001236&amp;u=https%3A%2F%2Fwww.aura.com%2F&amp;a=Aura">Aura</a>, the leading AI-powered online safety solution for individuals and families, today announced a strategic partnership with the leading family connection and safety company, Life360, whereby Life360 will invest $25 million in Aura and the two companies enter a commercial agreement for key go-to-market channels. Under the strategic partnership, Aura will have the exclusive right to sell Life360 as a bundled solution through its robust Employee Benefits channel. In addition Aura will begin a multi-year program of marketing directly to Life360 customers through the Life360 platform.&nbsp;

Life360 To Invest $25M In Aura; Two Companies Enter Commercial Agreement For Key Go-To-Market Channels

Stifel analyst W. Andrew Carter maintains Arhaus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARHS#NASDAQ">ARHS</a>) with a Buy and lowers the price target from $11.5 to $10.

ARHS

Stifel Maintains Buy on Arhaus, Lowers Price Target to $10

JP Morgan analyst Stanley Yang downgrades SK Telecom Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKM#NYSE">SKM</a>) from Overweight to Neutral.

Downgrades

JP Morgan Downgrades SK Telecom Co to Neutral

Fathom Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTHM#NASDAQ">FTHM</a>) is set to give its latest quarterly earnings report on Tuesday, 2025-05-13. Here's what investors need to know before the announcement.
Analysts estimate that Fathom Holdings will report an earnings per share (EPS) of $-0.08. 
Investors in Fathom Holdings are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Earnings History Snapshot</h3>
During the last quarter, the company reported an EPS missed by $0.12, leading to a 6.24% increase in the share price on the subsequent day.
Here's a look at Fathom Holdings's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.17</td>
<td>-0.12</td>
<td>-0.21</td>
<td>-0.25</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.29</td>
<td>-0.40</td>
<td>-0.22</td>
<td>-0.31</td>
</tr>
<tr>
<td>Price Change %</td>
<td>6.0%</td>
<td>-12.0%</td>
<td>-2.0%</td>
<td>-3.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1747073439_0.png" alt="eps graph" />
<h3>Performance of Fathom Holdings Shares</h3>
Shares of Fathom Holdings were trading at $0.82 as of May 09. Over the last 52-week period, shares are down 39.16%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/FTHM/earnings">To track all earnings releases for Fathom Holdings visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FTHM

Fathom Holdings Earnings Preview

Acumen Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABOS#NASDAQ">ABOS</a>) is preparing to release its quarterly earnings on Tuesday, 2025-05-13. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Acumen Pharmaceuticals to report an earnings per share (EPS) of $-0.51.
The market awaits Acumen Pharmaceuticals's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Past Earnings Performance</h3>
Last quarter the company missed EPS by $0.25, which was followed by a 3.25% drop in the share price the next day.
Here's a look at Acumen Pharmaceuticals's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.37</td>
<td>-0.36</td>
<td>-0.28</td>
<td>-0.26</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.62</td>
<td>-0.50</td>
<td>-0.34</td>
<td>-0.25</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-3.0%</td>
<td>-5.0%</td>
<td>-9.0%</td>
<td>3.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1747073429_0.png" alt="eps graph" />
<h3>Acumen Pharmaceuticals Share Price Analysis</h3>
Shares of Acumen Pharmaceuticals were trading at $0.9801 as of May 09. Over the last 52-week period, shares are down 71.54%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/ABOS/earnings">To track all earnings releases for Acumen Pharmaceuticals visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ABOS

A Preview Of Acumen Pharmaceuticals's Earnings

Stifel analyst Stephen Gengaro maintains Ameresco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMRC#NYSE">AMRC</a>) with a Buy and lowers the price target from $18 to $17.

AMRC

Stifel Maintains Buy on Ameresco, Lowers Price Target to $17

Cardano (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/ada/usd">ADA</a>) has surged 23% over the past week as <a href="https://www.benzinga.com/markets/25/04/45047461/i-dont-think-ethereum-will-survive-more-than-10-to-15-years-cardano-founder-charles-hoskinson-says">co-founder Charles Hoskinson</a> is exploring the possibility of launching a privacy-enabled stablecoin that functions with the anonymity of physical cash.
What Happened: Speaking on the Conversations with Leaders podcast hosted by eToro on May 9, Hoskinson said current stablecoins lack privacy and are too easily traceable on public blockchains like Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) and Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>), <a href="https://www.dlnews.com/articles/defi/cardano-founder-says-he-wants-to-create-a-privacy-stablecoin/?utm_source=telegram&amp;utm_medium=organic_social&amp;utm_campaign=">according</a> to DL News.
While stablecoins are a $243 billion market, their transactions remain fully visible, raising privacy concerns for users. 
Cardano currently supports stablecoins with a modest $31.5 million market cap, but Hoskinson hinted at making Cardano the first blockchain ecosystem to introduce a compliant yet privacy-preserving stablecoin.
Hoskinson argued that consumers might prefer not to have every purchase permanently recorded. 
He proposed selective disclosure as a possible solution, enabling privacy in daily transactions while still allowing necessary regulatory access for law enforcement and financial compliance. 
This concept, however, is not without precedent or controversy.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45352237/nakamoto-holdings-raises-710m-merges-with-kindlymd-to-build-bitcoin-treasury-holding-company">Nakamoto Holdings Raises $710M, Merges With KindlyMD To Build Bitcoin Treasury Holding Company</a>
Other privacy-centric projects such as Monero, Zcash and Firo have previously attempted to balance user privacy with regulatory demands.
Strategies like whitelisted addresses and shielded transactions were designed to retain anonymity while permitting certain institutions to verify transactions. 
Why It Matters: Despite these efforts, major regulators and exchanges have remained cautious, leading to delistings and declining liquidity in these assets.
The pressure is mounting from regulators worldwide. 
The European Union plans to prohibit privacy coins on exchanges and custodial platforms by July 2027, a move that signals further regulatory tightening. In the United States, efforts to pass federal legislation on stablecoins have faced setbacks. 
Last week, the GENIUS Act, a key stablecoin bill, failed to pass the Senate after objections from lawmakers who cited risks to financial stability and consumer protection.
Hoskinson's idea comes at a time when regulatory environments are rapidly evolving, and projects are under increasing scrutiny for how they balance user rights with legal obligations. 
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45349057/strategy-buys-134b-in-bitcoin-at-99856-cites-155-btc-yield">Strategy Buys $1.34B In Bitcoin At $99,856, Cites 15.5% BTC Yield</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$ADA

$ETH

$SOL

GRYP

Cardano Up 23% In 7 Days As Co-Founder Charles Hoskinson Explores Privacy-Focused Stablecoin

Actelis Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASNS#NASDAQ">ASNS</a>) will release its quarterly earnings report on Tuesday, 2025-05-13. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Actelis Networks to report an earnings per share (EPS) of $-0.25.
The market awaits Actelis Networks's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Performance in Previous Earnings</h3>
In the previous earnings release, the company missed EPS by $0.23, leading to a 2.91% drop in the share price the following trading session.
Here's a look at Actelis Networks's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.02</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.25</td>
<td>-0.09</td>
<td>-0.01</td>
<td>-0.5</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-3.0%</td>
<td>-5.0%</td>
<td>11.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>

<h3>Stock Performance</h3>
Shares of Actelis Networks were trading at $0.748 as of May 09. Over the last 52-week period, shares are up 41.56%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<a href="https://www.benzinga.com/quote/ASNS/earnings">To track all earnings releases for Actelis Networks visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ASNS

Actelis Networks Earnings Preview

Allogene Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLO#NASDAQ">ALLO</a>) is gearing up to announce its quarterly earnings on Tuesday, 2025-05-13. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Allogene Therapeutics will report an earnings per share (EPS) of $-0.27.
Investors in Allogene Therapeutics are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Earnings History Snapshot</h3>
During the last quarter, the company reported an EPS beat by $0.06, leading to a 2.65% increase in the share price on the subsequent day.
Here's a look at Allogene Therapeutics's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.34</td>
<td>-0.33</td>
<td>-0.35</td>
<td>-0.41</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.28</td>
<td>-0.32</td>
<td>-0.35</td>
<td>-0.38</td>
</tr>
<tr>
<td>Price Change %</td>
<td>3.0%</td>
<td>-3.0%</td>
<td>-4.0%</td>
<td>2.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1747073379_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Allogene Therapeutics were trading at $1.16 as of May 09. Over the last 52-week period, shares are down 59.8%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/ALLO/earnings">To track all earnings releases for Allogene Therapeutics visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALLO

Allogene Therapeutics's Earnings Outlook

Lexicon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>) is gearing up to announce its quarterly earnings on Tuesday, 2025-05-13. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Lexicon Pharmaceuticals will report an earnings per share (EPS) of $-0.10.
Investors in Lexicon Pharmaceuticals are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Historical Earnings Performance</h3>
In the previous earnings release, the company beat EPS by $0.03, leading to a 6.55% increase in the share price the following trading session.
Here's a look at Lexicon Pharmaceuticals's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.12</td>
<td>-0.16</td>
<td>-0.19</td>
<td>-0.2</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.09</td>
<td>-0.18</td>
<td>-0.17</td>
<td>-0.2</td>
</tr>
<tr>
<td>Price Change %</td>
<td>7.000000000000001%</td>
<td>-8.0%</td>
<td>-16.0%</td>
<td>2.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1747073368_0.png" alt="eps graph" />
<h3>Performance of Lexicon Pharmaceuticals Shares</h3>
Shares of Lexicon Pharmaceuticals were trading at $0.701 as of May 09. Over the last 52-week period, shares are down 64.06%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<h3>Analyst Insights on Lexicon Pharmaceuticals</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Lexicon Pharmaceuticals.
Analysts have given Lexicon Pharmaceuticals a total of 5 ratings, with the consensus rating being Buy. The average one-year price target is $3.8, indicating a potential 442.08% upside.
<h3>Peer Ratings Comparison</h3>
The following analysis focuses on the analyst ratings and average 1-year price targets of Abeona Therapeutics, 2seventy bio and Vanda Pharmaceuticals, three prominent industry players, providing insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Buy trajectory for Abeona Therapeutics, with an average 1-year price target of $16.5, suggesting a potential 2253.78% upside.</li>
<li>Analysts currently favor an Neutral trajectory for 2seventy bio, with an average 1-year price target of $5.0, suggesting a potential 613.27% upside.</li>
<li>Analysts currently favor an Buy trajectory for Vanda Pharmaceuticals, with an average 1-year price target of $20.0, suggesting a potential 2753.07% upside.</li>
</ul>
<h3>Analysis Summary for Peers</h3>
The peer analysis summary offers a detailed examination of key metrics for Abeona Therapeutics, 2seventy bio and Vanda Pharmaceuticals, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lexicon Pharmaceuticals</td>
<td>Buy</td>
<td>3682.62%</td>
<td>$26.21M</td>
<td>-20.81%</td>
</tr>
<tr>
<td>Abeona Therapeutics</td>
<td>Buy</td>
<td>0.00%</td>
<td>$0</td>
<td>-20.70%</td>
</tr>
<tr>
<td>2seventy bio</td>
<td>Neutral</td>
<td>-72.61%</td>
<td>$-5.92M</td>
<td>-8.89%</td>
</tr>
<tr>
<td>Vanda Pharmaceuticals</td>
<td>Buy</td>
<td>17.48%</td>
<td>$50.59M</td>
<td>-0.91%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Lexicon Pharmaceuticals ranks highest in Revenue Growth among its peers. It has the lowest Gross Profit margin. The company has the lowest Return on Equity.
<h3>Delving into Lexicon Pharmaceuticals's Background</h3>
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
<h3>Financial Milestones: Lexicon Pharmaceuticals's Journey</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Lexicon Pharmaceuticals's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 3682.62%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -127.16%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -20.81%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -10.9%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Lexicon Pharmaceuticals's debt-to-equity ratio surpasses industry norms, standing at 0.74. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<a href="https://www.benzinga.com/quote/LXRX/earnings">To track all earnings releases for Lexicon Pharmaceuticals visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

LXRX

A Preview Of Lexicon Pharmaceuticals's Earnings

Truist Securities analyst Mark Hughes maintains Main Street Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAIN#NYSE">MAIN</a>) with a Hold and lowers the price target from $62 to $54.

MAIN

Truist Securities Maintains Hold on Main Street Capital, Lowers Price Target to $54

JP Morgan analyst Rahul Krotthapalli maintains Sweetgreen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SG#NYSE">SG</a>) with a Neutral and lowers the price target from $25 to $20.

JP Morgan Maintains Neutral on Sweetgreen, Lowers Price Target to $20

Southwest Gas Holdings shares are trading lower after the company reported a Q1 sales miss.

Iterum Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITRM#NASDAQ">ITRM</a>) is preparing to release its quarterly earnings on Tuesday, 2025-05-13. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Iterum Therapeutics to report an earnings per share (EPS) of $-0.23.
The market awaits Iterum Therapeutics's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Earnings Track Record</h3>
Last quarter the company beat EPS by $0.12, which was followed by a 0.0% drop in the share price the next day.

<img src="https://www.benzinga.com/files/images/story/2025/1747073325_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Iterum Therapeutics were trading at $1.02 as of May 09. Over the last 52-week period, shares are down 30.67%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/ITRM/earnings">To track all earnings releases for Iterum Therapeutics visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ITRM

A Look Ahead: Iterum Therapeutics's Earnings Forecast

BofA Securities analyst Justin Post maintained a Buy rating on Amazon.Com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) on Monday with a <a href="https://www.benzinga.com/quote/AMZN/analyst-ratings" target="_blank" rel="noreferrer noopener">price target of $230</a>.
Last week, Amazon announced eight new robots at its Delivering the Future event, including seven for its delivery stations and one for fulfillment centers, Post said.
Robots, including Tipper, ZancaSort, and Agility, can sort packages more efficiently, while Echelon and Vision-Assorted Sort Station can assist with handling.
Also Read: <a target="_blank" href="https://www.benzinga.com/media/25/02/43972083/amazons-25-billion-robotics-push-targets-cost-savings-ai-growth-and-temu-competition-report" rel="noreferrer noopener">Amazon&#8217;s $25 Billion Robotics Push Targets Cost Savings, AI Growth And Temu Competition: Report</a>
In fulfillment centers, Vulcan can pick and stow items from pods using a combination of built-in conveyor belts and suction cups.
Vulcan can &#8220;feel&#8221; items with force feedback sensors and avoid damaging items. According to Amazon, robots help with about 75% of customer orders, but robot touchpoints per package will likely increase as Amazon introduces more robot types.
The post highlighted Amazon&#8217;s close to 1 million logistics and fulfillment employees, which can have 50% annual churn, and robotics can help solve potential long-term staffing bottlenecks.
On Amazon&#8217;s first-quarter earnings call, CEO Andy Jassy said robotics will be key to improving its cost structure, fine-tuning the company&#8217;s inbound network, and building out same-day delivery sites.
Post also noted that the cost savings enabled by robotics would open more rural areas to same-day delivery.
Robots can drive cost efficiencies by reducing labor costs, employee injury costs, higher utilization of Amazon&#8217;s warehouses, and order accuracy. This, in turn, decreases the number of product returns. Per MWPVL, returns can be approximately 20% of total fulfillment and delivery costs, the analyst said.
Amazon indicated that the company &#8220;is now ready to implement these innovations at scale,&#8221; though some robots will not likely launch until 2027.
Still, Amazon is already experimenting with robotics at its new 12 Generation Fulfillment Center, which opened in late 2024. This facility, located in Shreveport, Louisiana, spans more than 3 million square feet and houses 10 times more robots than previous generations.
According to Jassy, 12 Generation Fulfillment Centers can &#8220;reduce fulfillment processing time by up to 25%, increase the number of items we can offer for same-day or next-day delivery, and is expected to drive a 25% improvement in our cost to serve during peak&#8221;.
With fulfillment costs at $99 billion in 2024, even a 10% savings could add $10 billion in profits to the bottom line.
Amazon&#8217;s robotic efforts thus far have been mainly focused on fulfillment, which, according to Post, represents around 17% of Amazon&#8217;s total costs (and 15% of total revenues).
Delivery could be another area of material cost savings, with shipping costs representing another 17% of Amazon&#8217;s total costs (and 15% of total revenues).
With Zoox AV capabilities ramping up and more efficient MK30 drones launched late in 2024 (Amazon aims to deliver 500 million packages by drone annually by 2030), Post noted Amazon will also be able to find long-term cost savings in delivery, leveraging the company&#8217;s AI technical expertise.
Price Action: AMZN stock is up 7.9% at $208.49 at the last check on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/media/25/03/44544278/softbank-looks-at-investing-1-trillion-for-us-ai-push-with-robot-run-industrial-parks" target="_blank" rel="noreferrer noopener">SoftBank Looks At Investing $1 Trillion For US AI Push With Robot-Run Industrial Parks</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Reiteration

Trading Ideas

AMZN

Why Amazon's Robot Army Could Save $10 Billion And Change Your Delivery Game

APGE

Apogee Therapeutics shares are trading higher after the company reported a Q1 EPS beat.

Contracts

Press Releases

Junee Limited's Subsidiary ASPAC AI Computing Enters Strategic Agreement with PanaAI Technology for Advanced AI Infrastructure

Junee Limited Announces Financing Round of Up to US$40 Million to Establish AI (Artificial Intelligence) Supercomputing Center in Australia

Junee Limited Announces the Acquisition of a 51% Stake in MindEnergy, a Provider of AI Server Design and Software Solutions, Aiming to Accelerate the Development of AI Training and Inference Servers and Enhance AI Computing Capabilities Using Advanced Open-Source AI Models Such as DeepSeek R1 and Meta Llama 3

Comments

Junee

Noticias

Últimas noticias sobre Junee (NASDAQ:JUNE) Bolsa

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL